Home LiteratureArticle Details
PMID: 21156280 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

Cancer cell ·Vol. 18 ·No. 6 ·2010-12-14 ·Pages 548-51

Gerber DE, Minna JD

Abstract

It was only 3 years ago that an acquired translocation of EML4 with ALK leading to the expression of an EML4-ALK oncoprotein in non-small cell lung cancer (NSCLC) was reported. Tumor cells expressing EML4-ALK are "addicted" to its continued function. Now, crizotinib, an oral ALK inhibitor, is demonstrated to provide dramatic clinical benefit with little toxicity in patients having such advanced NSCLC, and a mechanism of clinical resistance to crizotinib is identified. Such therapy "targeted" at oncogenic proteins provides "personalized" medicine and prompts genome-wide mutation analysis of human tumors to find other therapeutic targets.

MeSH Terms
Anaplastic Lymphoma Kinase Carcinoma, Non-Small-Cell Lung/drug therapy Clinical Trials as Topic Drug Discovery Humans Lung Neoplasms/drug therapy Protein Kinase Inhibitors/therapeutic use Protein-Tyrosine Kinases/antagonists & inhibitors Receptor Protein-Tyrosine Kinases Translational Research, Biomedical
Chemicals
Protein Kinase Inhibitors ALK protein, human Anaplastic Lymphoma Kinase Protein-Tyrosine Kinases Receptor Protein-Tyrosine Kinases
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Gerber David E
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, 75390, USA. david.gerber@utsouthwestern.edu
Minna John D
References (30)
30 references, click to expand
  1. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
    J Clin Oncol. 2008 May 20;26(15):2450-6 PMID: 18378568
  2. The mutation spectrum revealed by paired genome sequences from a lung cancer patient.
    Nature. 2010 May 27;465(7297):473-7 PMID: 20505728
  3. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.
    Cancer Res. 2007 May 1;67(9):4408-17 PMID: 17483355
  4. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
    Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22 PMID: 18089725
  5. Characterizing the cancer genome in lung adenocarcinoma.
    Nature. 2007 Dec 6;450(7171):893-8 PMID: 17982442
  6. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
    Science. 1994 Mar 4;263(5151):1281-4 PMID: 8122112
  7. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
    Eur J Cancer. 2010 Sep;46(13):2357-68 PMID: 20451371
  8. Diverse somatic mutation patterns and pathway alterations in human cancers.
    Nature. 2010 Aug 12;466(7308):869-73 PMID: 20668451
  9. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
    N Engl J Med. 2010 Oct 28;363(18):1727-33 PMID: 20979472
  10. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
    J Clin Oncol. 2009 Sep 10;27(26):4247-53 PMID: 19667264
  11. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer.
    Nucleic Acids Res. 2010 Jan;38(Database issue):D652-7 PMID: 19906727
  12. Oncogene addiction.
    Cancer Res. 2008 May 1;68(9):3077-80; discussion 3080 PMID: 18451130
  13. Somatic mutations affect key pathways in lung adenocarcinoma.
    Nature. 2008 Oct 23;455(7216):1069-75 PMID: 18948947
  14. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
    N Engl J Med. 2010 Oct 28;363(18):1734-9 PMID: 20979473
  15. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
    J Clin Oncol. 2005 Sep 1;23(25):5892-9 PMID: 16043829
  16. Towards patient-based cancer therapeutics.
    Nat Biotechnol. 2010 Sep;28(9):904-6 PMID: 20829823
  17. High-throughput oncogene mutation profiling in human cancer.
    Nat Genet. 2007 Mar;39(3):347-51 PMID: 17293865
  18. A small-cell lung cancer genome with complex signatures of tobacco exposure.
    Nature. 2010 Jan 14;463(7278):184-90 PMID: 20016488
  19. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.
    Oncogene. 2010 Apr 22;29(16):2346-56 PMID: 20118985
  20. Cancer statistics, 2010.
    CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 PMID: 20610543
  21. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.
    Cancer Res. 2008 Jul 1;68(13):4971-6 PMID: 18593892
  22. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
    Nature. 2007 Aug 2;448(7153):561-6 PMID: 17625570
  23. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
    Clin Cancer Res. 2009 Aug 15;15(16):5216-23 PMID: 19671850
  24. Targeted therapy in non-small-cell lung cancer--is it becoming a reality?
    Nat Rev Clin Oncol. 2010 Jul;7(7):401-14 PMID: 20551945
  25. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.
    Clin Cancer Res. 2010 Nov 15;16(22):5581-90 PMID: 21062932
  26. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.
    Cancer Cell. 2010 Jan 19;17(1):77-88 PMID: 20129249
  27. A mouse model for EML4-ALK-positive lung cancer.
    Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19893-7 PMID: 19064915
  28. The (r)evolution of cancer genetics.
    BMC Biol. 2010 Jun 11;8:74 PMID: 20594288
  29. Network of Cancer Genes: a web resource to analyze duplicability, orthology and network properties of cancer genes.
    Nucleic Acids Res. 2010 Jan;38(Database issue):D670-5 PMID: 19906700
  30. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
    N Engl J Med. 2010 Oct 28;363(18):1693-703 PMID: 20979469
Article Info
Journal
Cancer cell
Abbr.
Cancer Cell
ISSN
1878-3686
DOI
10.1016/j.ccr.2010.11.033
Email
david.gerber@utsouthwestern.edu
Published
2010-12-14
Pages
548-51
Language
English
Region
United States
NLM ID
101130617
PMCID
PMC3110762
Subset
IM
Grants
NCI NIH HHS · P50 CA070907 · United States
NCI NIH HHS · P50 CA070907-14 · United States
NCI NIH HHS · P50CA70907 · United States
External Links
PubMed source DOI: 10.1016/j.ccr.2010.11.033 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2